Antiviral Discovery for Highly Pathogenic Emerging Viruses
Royal Society of Chemistry (Verlag)
978-1-78801-564-6 (ISBN)
Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.
Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets;
Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Fevers;
Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic;
Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses;
Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies;
Vaccine Development in the Midst of Ebolavirus Disease Outbreaks;
Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Viruses;
Therapeutics Against Nipah and Hendra Virus;
Glycomimetics as Promising Inhibitors of Ebola Virus, Flavivirus and HIV Infections;
Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses;
Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses
Erscheinungsdatum | 08.12.2021 |
---|---|
Reihe/Serie | Drug Discovery ; Volume 80 |
Verlagsort | Cambridge |
Sprache | englisch |
Maße | 156 x 234 mm |
Gewicht | 606 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie | |
Naturwissenschaften ► Chemie ► Organische Chemie | |
ISBN-10 | 1-78801-564-9 / 1788015649 |
ISBN-13 | 978-1-78801-564-6 / 9781788015646 |
Zustand | Neuware |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich